EPISODE · Jul 18, 2023 · 8 MIN
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
from PeerVoice Clinical Pharmacology Video · host PeerVoice
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Embed this episode
What this episode covers
Visit https://www.peervoice.com/RKE860 to view the entire programme with slides. After completing “Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses”, participants will be able to: Summarise the most recent clinical data for radioligand therapy (RLT) for the management of men with metastatic castration-resistant prostate cancer (mCRPC); Evaluate how these data add to previous knowledge about the management of mCRPC with RLT; and Discuss the clinical implications of these data in the context of current treatment paradigms for mCRPC.
Ready to play
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
No transcript for this episode yet
Similar Episodes
No similar episodes found.